Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)

The COVID-19 pandemic has brought significant changes and advances in the field of vaccination, including the implementation and widespread use of encapsidated mRNA vaccines in general healthcare practice. Here, we present two new mRNAs expressing antigenic parts of the SARS-CoV-2 spike protein and provide data supporting their functionality. The first mRNA, called RBD-mRNA, encodes a trimeric form of the virus spike protein receptor binding domain (RBD). The other mRNA, termed T-mRNA, codes for the relevant HLA I and II spike epitopes. The two mRNAs (COVARNA mRNAs) were designed to be used for delivery to cells in combination, with the RBD-mRNA being the primary source of antigen and the T-mRNA working as an enhancer of immunogenicity by supporting CD4 and CD8 T-cell activation. This innovative approach substantially differs from other available mRNA vaccines, which are largely directed to antibody production by the entire spike protein. In this study, we first show that both mRNAs are functionally transfected into human antigen-presenting cells (APCs). We obtained peripheral blood mononuclear cell (PBMC) samples from three groups of voluntary donors differing in their immunity against SARS-CoV-2: non-infected (naïve), infected-recovered (convalescent), and vaccinated. Using an established method of co-culturing autologous human dendritic cells (hDCs) with T-cells, we detected proliferation and cytokine secretion, thus demonstrating the ability of the COVARNA mRNAs to activate T-cells in an antigen-specific way. Interestingly, important differences in the intensity of the response between the infected-recovered (convalescent) and vaccinated donors were observed, with the levels of T-cell proliferation and cytokine secretion (IFNγ, IL-2R, and IL-13) being higher in the vaccinated group. In summary, our data support the further study of these mRNAs as a combined approach for future use as a vaccine.

[1]  P. Stefanelli,et al.  Omicron variant evolution on vaccines and monoclonal antibodies , 2023, Inflammopharmacology.

[2]  D. Lye,et al.  Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore , 2022, The Lancet Regional Health - Western Pacific.

[3]  A. Bertoletti,et al.  A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines , 2022, Cell Reports Medicine.

[4]  A. Bertoletti,et al.  SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic , 2022, Immunity.

[5]  M. Verdonck,et al.  A synthetic DNA template for fast manufacturing of versatile single epitope mRNA , 2022, Molecular therapy. Nucleic acids.

[6]  J. Sullivan,et al.  Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Sette,et al.  NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses , 2022, bioRxiv.

[8]  Christian A. Choe,et al.  Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics , 2022, Nature Communications.

[9]  K. Kedzierska,et al.  Count on us: T cells in SARS-CoV-2 infection and vaccination , 2022, Cell Reports Medicine.

[10]  Irena Vlatkovic,et al.  COVID-19 mRNA vaccines: Platforms and current developments , 2022, Molecular Therapy.

[11]  P. Sopp,et al.  An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease , 2021, Nature Immunology.

[12]  Aaron M. Rosenfeld,et al.  Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses , 2021, Immunity.

[13]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[14]  A. Sette,et al.  Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells , 2021, Science.

[15]  D. Weissman,et al.  mRNA vaccines for infectious diseases: principles, delivery and clinical translation , 2021, Nature Reviews Drug Discovery.

[16]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[17]  M. Beltramello,et al.  SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape , 2021, Nature.

[18]  P. Dormitzer,et al.  BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans , 2021, Nature.

[19]  R. Xu,et al.  mRNA vaccines for COVID-19: what, why and how , 2021, International journal of biological sciences.

[20]  Yonghong Tang,et al.  Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection , 2021, Nature Communications.

[21]  Felipe García,et al.  In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure? , 2021, Viruses.

[22]  Charles Y. Tan,et al.  BNT162b vaccines protect rhesus macaques from SARS-CoV-2 , 2021, Nature.

[23]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[24]  G. MacBeath,et al.  Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein , 2020, Immunity.

[25]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[26]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[27]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[28]  G. Kroemer,et al.  Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses , 2020, Cell stress.

[29]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[30]  Felipe García,et al.  Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[31]  C. Brander,et al.  Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix) , 2016, AIDS.

[32]  O. Boyman,et al.  Interleukin-2: Biology, Design and Application. , 2015, Trends in immunology.

[33]  B. Neyns,et al.  A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  P. Eilers,et al.  A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. , 2012, Clinical immunology.

[35]  J. Aerts,et al.  Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells. , 2010, Human gene therapy.

[36]  T. Malek,et al.  The biology of interleukin-2. , 2008, Annual review of immunology.

[37]  Houping Ni,et al.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.

[38]  F. Brasseur,et al.  Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules1 , 2004, The Journal of Immunology.

[39]  M. Norcross,et al.  Natural Truncation of the Chemokine MIP-1β/CCL4 Affects Receptor Specificity but Not Anti-HIV-1 Activity* , 2002, The Journal of Biological Chemistry.

[40]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.